Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales of blood collection tube preparation equipment and systems grew in both the domestic and overseas markets. In Japan, equipment and system projects for large-scale facilities progressed steadily, while overseas sales of compact models grew in the Asian market. Selling, general and administrative expenses decreased, mainly because research and development expenses were lower than in the previous fiscal year.
No applicable matters (There are no applicable matters.)
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥11,236,606 thousand (YoY +13.4%) |
| Operating profit | ¥1,668,321 thousand (YoY +28.3%) |
| Ordinary income | ¥1,717,693 thousand (YoY +31.8%) |
| Profit attributable to owners of the parent | ¥1,070,987 thousand (YoY +6.6%) |
| Net income per share | ¥155.28 |
| Equity ratio | End of the current fiscal period 80.2 / End of previous period 80.2 |
| Total assets | ¥17,966,466 thousand |
| Net assets | ¥14,410,459 thousand |
| Cash flows from operating activities | ¥1,100,442 thousand |
| Cash flows from investing activities | ¥-39,757 thousand |
| Cash flows from financing activities | ¥-1,145,845 thousand |
| Cash and cash equivalents at end of period | ¥8,976,227 thousand |
| Full-year earnings forecast | Reporting period Fiscal year ending March 2027 / Net Sales ¥10,300 million / Operating profit ¥1,100 million / Ordinary income ¥1,100 million / Net income ¥770 million |
| Regional sales | Current fiscal year Region Japan / Net Sales ¥9,803,025 thousand, Region Europe / Net Sales ¥117,406 thousand, Region Latin America and the Caribbean / Net Sales ¥141,735 thousand, Region Asia / Net Sales ¥1,140,793 thousand, Region Other overseas / Net Sales ¥33,645 thousand / Previous fiscal year Region Japan / Net Sales ¥8,543,363 thousand, Region Europe / Net Sales ¥108,349 thousand, Region Latin America and the Caribbean / Net Sales ¥108,264 thousand, Region Asia / Net Sales ¥1,093,767 thousand, Region Other overseas / Net Sales ¥52,119 thousand |
| Depreciation and amortization | ¥92,369 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income No / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥26 thousand, Item Provision for losses related to the discontinuation of manufacturing / Amount ¥192,500 thousand |
| Disclosure regarding the going concern assumption | No applicable matters (There are no applicable matters.) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | Sales of blood collection tube preparation equipment and systems grew in both the domestic and overseas markets. In Japan, equipment and system projects for large-scale facilities progressed steadily, while overseas sales of compact models grew in the Asian market. Selling, general and administrative expenses decreased, mainly because research and development expenses were lower than in the previous fiscal year. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of blood collection tube preparation equipment and systems grew in both the domestic and overseas markets. Sales to planned large-scale facility projects and sales of compact models in the Asian market progressed steadily. Selling, general and administrative expenses decreased, mainly because research and development expenses were lower than in the previous fiscal year. Meanwhile, costs associated with discontinuing the manufacture of certain models of blood collection tube preparation equipment were recorded as extraordinary losses.